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PB 2151 | Heparin Calibrated Anti-Xa Assays 
for the Measurement of Low Levels of Direct 
Factor Xa Inhibitors
L. Sabor1, M. Raphaël2, J.-M. Dogné2, F. Mullier2, J. Douxfils2
1CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Université 
Catholique de Louvain, Hematology Laboratory, Yvoir, Belgium, 2University of 
Namur, Namur Thrombosis and Hemostasis Center (NTHC), Department of 
Pharmacy, Namur, Belgium
Background: Apixaban, edoxaban and rivaroxaban do not require fre-
quent monitoring but an assessment of the intensity of anticoagula-
tion may be required in emergent or elective surgery. Some experts 
reported that anti-Xa activity below 0.1 IU/mL using heparin cali-
brated chromogenic assays may assert the absence of clinically rele-
vant (i.e. < 30 or < 50 ng/mL depending on the clinical situation) direct 
factor Xa levels. However, it is not clear if difference in response will 
depend on the anti-Xa agent and also on the chromogenic anti-Xa kit 
used to assess the anti-Xa activity.
Aims: To assess if a cut-off of 0.1 UI anti-Xa/mL is able to exclude 
apixaban, rivaroxaban or edoxaban concentration < 30 ng/mL or < 
50 ng/mL using different heparin calibrated chromogenic anti-Xa kits.
Methods: Apixaban, edoxaban and rivaroxaban were added to normal 
pooled plasma at increasing concentrations ranging from 0 to 500 ng/
mL. Anti-Xa activities were measured using 
(1) STA®-Liquid Anti-Xa (STA®LAX) on a STA-R Evolution 
Coagulometer, 
(2) Biophen®Heparin LRT (BP®LRT) on a STA-R Evolution coagulom-
eter and 
(3) HemosIL®-Liquid Anti-Xa (IL®LAX) on a ACL-TOP 700 according 
to manufacturer recommendations.
Results: At 30 ng/mL of rivaroxaban, BP®LRT, STA®LAX and IL®LAX 
provided anti-Xa results >0.1 IU/mL. At 30 ng/mL of apixaban or 
edoxaban, BP®LRT and IL®LAX were below the cut-off but the 
STA®LAX was not. At a concentration of 50 ng/mL, only edoxaban 
with the BP®LRT kit showed an anti-Xa activity < 0.1 UI/mL. 
Conclusions: Low (< 0.1 IU/mL) anti-Xa activity is not safe to exclude 
clinically relevant direct factor Xa levels and should be avoided. It can 
only inform if the drug is present or not. Chromogenic anti-Xa assays 
calibrated against the appropriate agent and using the appropriate 
procedure remains the more accurate method to assess accurately 
low levels of direct FXa inhibitors. 
PB 2152 | Efficacy of a Novel Contact Pathway 
Inhibitor, Ir-CPI, on in vitro Clotting Induced by 
PCI Catheter Segment
J. Douxfils1, D. Gheldof1, S. Derochette2, J. Tassignon2, 
C. Meinguet2, M. Guyaux2, J.-M. Dogné1, E. Godfroid2
1University of Namur, Pharmacy, Namur, Belgium, 2Bioxodes, Marche-en-Famenne, 
Belgium
Background: Ir-CPI, a protein derived from the tick Ixodes ricinus sali-
vary, is a serine protease inhibitor of both factor XIa (FXIa) and FXIIa. 
In patients undergoing percutaneous coronary intervention (PCI), cath-
eter thrombosis may occur as catheters trigger activation of FXII/FXI.
Aims: The aim of this study was to evaluate the effect of Ir-CPI on in 
vitro clotting induced by PCI catheter segment.
Methods: Catheter segments were pressed flat, shaped into rings 
and placed around the perimeter of wells (96-well plate), leaving the 
center of the well unobstructed. To the wells were added serial dilu-
tion of Ir-CPI (until 10 μM) with normal pooled plasma (NPP) or plas-
mas deficient in FXI or FXII. After incubation at 37°C and addition of a 
CaCl2 solution, clot formation was assessed by monitoring absorbance 
at 340nm. Time to reach one-half maximal absorbance (IC50) was de-
fined as the clotting time. Thrombin generation test (TGT) was also 
assessed using catheter segment as trigger of the process. Positive 
inhibitory controls were used (fondaparinux, enoxaparin).
Results: Presence of the catheter reduced the clotting time of NPP; 
an effect reversed by the addition of Ir-CPI. At high concentrations 
(≥ 5μM), Ir-CPI allowed to overpass the clotting time without cath-
eter. On TGT (Fig 1), catheter segments decreased lag time and time 
T A B L E  1 Anti-Xa activities using STA®LAX on a STA-R Evolution 
Coagulometer, BP®LRT on a STA-R Evolution coagulometer and (3) 
IL®LAX on a ACL-TOP 700
concentra-
tion (ng/mL) anticoagulant
STA®LAX 
(UI/mL)
BP®LRT
(UI/mL)
IL®LAX(UI/
mL)
30 Rivavoxaban 0,19 0,12 0,08
30 Apixaban 0,09 0,03 0,04
30 Endoxaban 0,07 0,02 0,02
50 Rivavoxaban 0,45 0,34 0,16
50 Apixaban 0,17 0,10 0,07
50 Endoxaban 0,13 0,06 0,04
F I G U R E  1 Effect of Ir-CPI on Thrombin Generation Time (TGT) in 
NPP exposed to PCI catheter segments
